Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06263517
Other study ID # SPA-S-899-01-21
Secondary ID 2021-003124-33
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date October 12, 2023
Est. completion date October 2025

Study information

Verified date January 2024
Source SPA Società Prodotti Antibiotici S.p.A.
Contact Maria Rosa Galmozzi
Phone 0289139429
Email mariarosa.galmozzi@spafarma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to to clarify which is the best dose of administration, to select a dose and to confirm the therapeutic efficacy of clodronate in patients with painful knee osteoarthritis (OA). The clinical trial will be divided in two parts. The main questions it aims to answer are: - in Phase II, to assess the safety and tolerability of different escalating doses of intra articular (IA) clodronate - in Phase II, to set a defined therapeutic dose (DTD) to be used in Phase III - in Phase III, to assess the safety and tolerability of different escalating doses of IA clodronate to confirm and extensively evaluate the therapeutic efficacy and safety of the clodronate DTD in patients with knee OA


Description:

The phase II will be a multicenter, double-blind, randomized, placebo-controlled, parallel group four-arm study, according to the treatment dose (dose finding). Briefly, 4 groups of 74 patients (in order to have 64 fully evaluated patients taking into consideration 10 patients dropped out), i.e. a total of 296 patients, with knee OA each will be randomly allocated to the following treatments: 1. IA clodronate 2 mg/2 ml once a week for 4 weeks (total clodronate dose = 8 mg). 2. IA clodronate 5 mg/2 ml once a week for 4 weeks (total clodronate dose = 20 mg). 3. IA clodronate 10 mg/2 ml once a week for 4 weeks (total clodronate dose = 40 mg). 4. Placebo 2 ml once a week for 4 weeks (total clodronate dose = 0 mg). At the end of phase II, the minimum effective clodronate dose will be selected as DTD for the Phase III. The phase III will be a multicenter, double-blind, randomized, placebo-controlled, two parallel groups (DTD vs. placebo) study. Briefly, patients with knee OA will be randomly assigned to two experimental groups: 1. the DTD defined during the Phase II. 2. Matching placebo. The sample size of Phase III will be definitively calculated according to the extent of pain Visual Analogue Scale (VAS) reduction observed in the Phase II.


Recruitment information / eligibility

Status Recruiting
Enrollment 296
Est. completion date October 2025
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender All
Age group 50 Years to 75 Years
Eligibility Inclusion Criteria: - Female and male patients aged 50 up to 75 years at ICF signature. - Diagnosis of knee OA according to the American College of Rheumatology, confirmed by Rx during the screening (a Rx performed in the last 3 months before Baseline is accepted). - Kellgren-Lawrence radiographic score between 2 and 3 degrees in the tibiofemoral joint. - Symptomatic knee OA (pain) since at least 6 months with a knee pain (VAS) ranging between 40 and 80 mm at Screening visit (the figure should be confirmed at Baseline). - Female patients of childbearing potential must have a negative pregnancy test before each treat-ment and during the Visit 5 - Week 4 and they must use adequate methods of contraception throughout the course of the study. - A signed ICF by the patient after exhaustive study discussion with the investigators. Exclusion Criteria: - BMI > 35 kg/m² (Class II obesity). - Joint instability due to other reasons than knee OA, such as f.i. algo dystrophic syndrome, either partial or complete rupture of internal / externals ligaments, kneecap instability, etc. - Otherwise located lower limb pain, such as hip pain. - Other musculoskeletal disorders related to the target knee. - Any treatment with IA drugs in the last 3 months before Day 0 - Baseline (including any formulation of corticosteroids or hyaluronic acid injections). - Corticosteroid use by any systemic route, and hyaluronic acid injection or intraarticular corticosteroids for any other joint in the previous month will not be permitted. - Any treatment with systemic non-steroidal anti-inflammatory drugs (NSAIDs) in the week before enrolment, or any steroid anti-inflammatory drugs and chondroprotective drugs in the thirty (30) days before month before Baseline. - Any treatment with systemic bisphosphonates in the last twelve (12) months before Baseline. - Any treatment with Glucosamine or Chondroitin sulfate, Diacerein and Matrix metalloproteinase (MMP) inhibitors in the 4 weeks before Baseline. - Any treatment with Denosumab in the twelve (12) months before Baseline. - Any treatment with Paracetamol in the twelve (12) hours before Baseline. - Any knee surgery in the past or knee arthroplasty. - Any diagnostic or surgical arthroscopy of the knee in the six (6) months before Baseline. - Any jaw osteonecrosis in the last twenty-four (24) months before Baseline or at a risk of jaw osteonecrosis. - Any known hypersensitivity to the drug in the study to its excipients or other bisphosphonates, and any hypersensitivity to Paracetamol (rescue drug). - Any participation in a clinical study in which the last administration of the investigational medicinal product was within two (2) weeks before consenting to study participation (i.e.signing ICF). - Inadequate organ function defined by the following laboratory parameters: 1. Absolute Neutrophil Count (ANC) < 1500/µl. 2. Hemoglobin (Hb) < 9 g/dl (< Hb 5.6 mmol/L) 3. Platelet Count < 100.000/µl 4. Serum Creatinine > 1.5 x Upper limit normal (ULN) or estimated Glomerular Filtration Rate (eGFR) < 60 mL/min (as per Cockroft-Gault formula). 5. Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST)> 1.5 x Upper limit normal(ULN). 6. Serum Total Bilirubin > 1.5 x Upper limit normal (ULN). - Pregnant or breastfeeding women, or women planning to become pregnant during the study. - Any positive or suspected history of alcoholism or drug use. - Clinically significant (i.e.) gastrointestinal, renal, hepatic, pulmonary, cardiovascular or neurological disease that could interfere with the outcome of the study or the patient's ability to comply with study requirements. - Patients unwilling or unable to comply with the protocol.

Study Design


Intervention

Drug:
Clodronate
For Arm 1, patients will be treated with intra articular clodronate 2 mg/2 ml from Baseline to Week 3
Clodronate
For Arm 2, patients will be treated with intra articular clodronate 5 mg/2 ml from Baseline to Week 3
Clodronate
For Arm 3, patients will be treated with intra articular clodronate 10 mg/2 ml from Baseline to Week 3
Placebo
For Arm 4, patients will be treated with Placebo 2 ml from Baseline to Week 3

Locations

Country Name City State
Italy Centro Riabilitativo Polifunzionale Teresio Borsalino Alessandria
Italy IRCCS Istituti Clinici Maugeri Castel Goffredo Mantova
Italy Ospedale San Pellegrino Castiglione delle Stiviere Mantova
Italy IRCCS Ospedale Policlinico San Martino Genova
Italy Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano Torino
Italy Ospedale Israelitico Roma
Italy Ospedale San Pietro Rome
Italy Ospedale San Paolo Savona
Italy Azienda Ospedaliero Universitaria Senese Siena
Italy Ospedale Policlinico "G.B. Rossi" Borgo Roma Verona
Italy Ospedale Civile Servizio di Riabilitazione Funzionale Volta Mantovana Mantova

Sponsors (2)

Lead Sponsor Collaborator
SPA Società Prodotti Antibiotici S.p.A. Pharmaceutical Development and Services

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Other SAE Reporting Recording of Serious adverse event (SAE) and abnormal laboratory or any clinical signs of intolerance across the patients' visits. At Screening, at Baseline, at Weeks 1, 2, 3, 4, 5, 7, 11, 15
Other AE Reporting Recording of adverse event (AE) At Screening, at Baseline, at Weeks 1, 2, 3, 4, 5, 7, 11, 15
Other Clinical signs of intolerance Recording Recording of any clinical signs of intolerance across the patients' visits At Baseline, at Weeks 1, 2, 3, 4, 5, 7, 11, 15
Primary Efficacy: VAS Reduction A clodronate dose will be considered as effective when a = 10 mm reduction in the Visual Analogue Scale (VAS) of knee pain will be observed at Week 7 vs. Placebo Week 7
Secondary VAS mean changes Mean changes in the Visual Analogue Scale (VAS) of knee pain observed at each other visit than Week 7 vs. Placebo and vs Baseline. At Screening, at Baseline, at Weeks 1, 2, 3, 4, 5, 11, 15
Secondary VAS mean changes observed 120 minutes after IA Mean changes in the Visual Analogue Scale (VAS) of knee pain observed 120 minutes after IA injection at Baseline, Weeks 1, 2 and 3 vs predose assessment At Baseline and at Weeks 1, 2 and 3
Secondary Lequesne Algofunctional Index mean changes Mean changes in the Lequesne Algofunctional Index at each visit vs Placebo and vs Baseline. At Screening, at Baseline, at Weeks 1, 2, 3, 4, 5, 7, 11, 15
Secondary WOMAC mean changes Mean changes in the (WOMAC) Western Scale Ontario MacMaster Index at each visit vs Placebo and vs Baseline. At Screening, at Baseline, at Weeks 1, 2, 3, 4, 5, 7, 11, 15
Secondary Range of motion mean changes Mean changes in the Range of Motion at each visit vs Placebo and vs Baseline. At Screening, at Baseline, at Weeks 1, 2, 3, 4, 5, 7, 11, 15
Secondary Paracetamol consumption Use of rescue drug consumption (paracetamol) across the patients visits At Baseline, at Weeks 1, 2, 3, 4, 5, 7, 11, 15
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03274713 - Efficacy of Electro-acupuncture Versus Manual Acupuncture on Knee Osteoarthritis N/A
Completed NCT04535596 - Blood Flow Restriction Exercises and Conservative Exercises in Knee Osteoarthritis N/A
Completed NCT03918291 - Whole-body Vibration Training on Functional Performance of the Elderly With Knee Osteoarthritis N/A
Completed NCT01453738 - Allogeneic Mesenchymal Stem Cells in Osteoarthritis Phase 2
Active, not recruiting NCT01027819 - Comparison of Outcomes in Mobile and Fixed-bearing Total Knee Arthroplasty Phase 4
Completed NCT01186211 - Feasibility of Outpatient Total Knee Arthroplasty
Active, not recruiting NCT00261066 - Outcome Following Orthopaedic Surgery
Completed NCT03484910 - Biofeedback With Cycling Exercise in OA Knee Patients N/A
Recruiting NCT03884374 - Pain Relief for OsteoArthritis Through Combined Treatment (PROACT) N/A
Completed NCT03492320 - Progression of Health Related Quality of Life of Patients Waiting for Total Knee Arthroplasty
Completed NCT01449552 - Temporary Clamping of Drains Combined With Tranexamic Acid Reduce Blood Loss After TKA: A Prospective RCT N/A
Completed NCT06254976 - Serum Nesfatin-1 and Human Cartilage Glycoprotein-39 Levels in Knee Osteoarthritis N/A
Completed NCT03428893 - Mobile Technology to Support Physical Therapy Exercise N/A
Completed NCT05081921 - Clinical Trial to Evaluate Safety and Efficacy of MesoCellA-Ortho Tissue-Engineered Advanced Therapy Product in Patients With Osteoarthrosis and Civilisation Diseases Phase 1/Phase 2
Completed NCT02850068 - Geniculate Artery Embolization for the Treatment of Knee Pain N/A
Active, not recruiting NCT03110172 - Short-term Efficacy of Antidepressant in Patients Underwent TKA Phase 1/Phase 2
Enrolling by invitation NCT02623660 - Microcurrent Stimulation Reduces Post-Operative Swelling and Healing Time Following Knee Replacement Surgery N/A
Completed NCT02579174 - Total Knee Replacement Component Alignment Using Manual Versus Custom Instrumentation N/A
Completed NCT00790985 - Efficacy of Flavocoxid 500 mg Compared With Naproxen 500 mg in Subjects With Moderate-severe Osteoarthritis of the Knee N/A
Recruiting NCT02722811 - Efficacy of Subcutaneous Injection of Etanercept for Moderate and Severe Knee Osteoarthritis N/A